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34 The Journal of Thoracic and Cardiobjectives: Ischemic spinal cord injury is a serious complication of aortic surgery.
lthough the extracellular signal-regulated kinases 1 and 2 are generally regarded as
elated to cell proliferation and survival, increasing evidence suggests that the role
f the extracellular signal-regulated kinase pathway in ischemia/reperfusion injury
s much more sophisticated.
ethods: Spinal cord ischemia in rats was induced by occluding the thoracic descend-
ng aorta with a balloon catheter introduced through a femoral artery, accompanied by
oncomitant exsanguination. Rats in the control group were given dimethyl sulfox-
de (vehicle) before undergoing spinal cord ischemia/reperfusion injury. In the
0126-treated group, rats were pretreated with a specific inhibitor of the mitogen-
ctivated protein kinase/extracellular signal-regulated kinases 1 and 2, U0126, to
nhibit extracellular signal-regulated kinases 1 and 2 phosphorylation. The sham-
perated rats underwent aortic catheterization without occlusion. Parameters, in-
luding neurologic performance, neuronal survival, inflammatory cell infiltration,
nd interleukin-1 production in the spinal cords, were compared between groups.
esults: Early extracellular signal-regulated kinases 1 and 2 phosphorylation was
bserved after injury in the control group, followed by abundant microglial accu-
ulation in the infarct area and increased interleukin-1 expression. In the U0126
roup, U0126 treatment completely blocked extracellular signal-regulated kinases 1
nd 2 phosphorylation. Microglial activation and spinal cord interleukin-1 levels were
ignificantly reduced. Neuronal survival and functional performance were improved.
onclusions: The mitogen-activated protein kinase/extracellular signal-regulated
inase pathway may play a noxious role in spinal cord ischemia/reperfusion injury
y participating in inflammatory reactions and cytokine production. Targeting this
athway may be of potential value in terms of therapeutic intervention.
itogen-activated protein kinase (MAPK) pathways are crucial signal
transducing cascades that transmit and integrate extracellular signals to
mount an appropriate response.1 Among the subgroups of the MAPKs,
he extracellular signal-regulated kinases 1 and 2 (ERK1/2), being phosphorylated
y MAPK/ERK 1 and 2 (MAPK/ERK kinase [MEK]1/2) in response to growth
actors,2,3 are generally regarded as being related to cell survival, proliferation, and
ifferentiation.4,5 However, emerging evidence suggests that activation of ERK1/2
ay lead to neuronal cell death.6-8 Inhibiting the MEK/ERK pathway was found to
rovide neuroprotection against oxidative stress,9 mechanical trauma,10 and seizure-
ike activity.11 In vivo studies showed that MEK/ERK inhibition decreased infarct
olume and improved neuronal survival in animal models of cerebral ischemia,12,13
s well as deep hypothermic circulatory arrest.14 Despite these findings, the role of
vascular Surgery ● April 2007
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Phe MEK/ERK pathway in ischemia/reperfusion (I/R) injury
f the central nervous system (CNS) has not been well
xplored.
Inflammation is a key pathologic feature of the CNS
gainst a variety of insults. Proinflammatory cytokines se-
reted by activated microglia and recruited astrocytes may
ontribute to neuronal degeneration and cell death.15-17 In-
erleukin (IL)-1, in particular, has been shown to play a
ivotal role in the development of acute neurodegenera-
ion caused by ischemic, excitotoxic, and traumatic brain
njury.18-20 Antagonizing IL-1 action reduced inflammation
nd neuronal loss in cerebral ischemia.21 Likewise, IL-1
eceptor null mice showed significantly milder brain edema
nd tissue damage after ischemic brain injury.22
It was recently demonstrated that MEK/ERK inhibition
ignificantly reduced infarct volume and proinflammatory
ytokine expression after cerebral ischemia, implicating that
he MEK/ERK pathway may be an important regulator of
nflammatory responses in the brain.23 In the present study,
e sought to clarify the role of the MEK/ERK pathway in
pinal cord I/R injury, a devastating complication after aortic
urgery. We hypothesized that this pathway is involved in
ediating inflammation and cytokine expression after spi-
al cord I/R injury. We also examined whether inhibiting
his pathway with the selective inhibitor U0126 could mit-
gate the severity of injury and provide neuroprotection.
aterials and Methods
xperimental Animals
dult male Sprague–Dawley rats weighing 350 to 400 g were
sed. Animals were housed 2 per cage, maintained on a 12-hour
ight-dark schedule at 22°C, and allowed free access to food and
ater. Animal care and procedures were conducted in compliance
ith the guidelines for animal experiments of the National Science
ouncil of this country.
nimal Model of Spinal Cord Ischemia/Reperfusion
njury
nesthesia was induced with 2% to 3% isoflurane in oxygen and
Abbreviations and Acronyms
CBP  carotid blood pressure
CNS  central nervous system
ERK  extracellular signal-regulated kinase
GFAP  glial fibrillary acidic protein
IL  interleukin
I/R  ischemia/reperfusion
MAPKmitogen-activated protein kinase
MEK MAPK/ERK kinase
MPO myeloperoxidase
p-ERK  phosphorylated extracellular signal-regulated
kinaseaintained with 1% to 2% isoflurane delivered through a face mask. a
The Journal of Thoracicectal temperature was monitored with a probe (RET-2, Physi-
emp Instruments, Inc, Clifton, NJ) and maintained at 37°C  0.5°C
ith the Deltaphase Isothermal Pad (Braintree Scientific, Inc, Brain-
ree, Mass). Spinal cord ischemia was induced by intraluminal
alloon occlusion of the descending thoracic aorta as previously
escribed.24 We applied concomitant hypovolemic hypotension
uring aortic occlusion, which we had found an effective modifi-
ation to ensure spinal cord I/R injury of the same severity.25 The
arotid blood pressure (CBP) was continuously monitored through
cannula in the left common carotid artery (PowerLab ADInstru-
ents, ADInstruments Pty Ltd, Castle Hill, Australia). A 2F
ogarty arterial embolectomy catheter (Baxter Healthcare Corpo-
ation, Irvine, Calif) was advanced 10 to 11 cm into the descending
horacic aorta through an incision on the left femoral artery. The
ight femoral artery was cannulated with a 24-gauge intravenous
annula. Blood was withdrawn into a heparinized syringe until the
ean CBP decreased to 50 mm Hg. The catheter balloon was
nflated to completely occlude the descending thoracic aorta for 5
inutes. The catheter balloon was then deflated, and the with-
rawn blood was slowly pushed into the right femoral artery to
estore normal blood volume.
xperimental Protocol
ats were randomly divided into 3 experimental groups. In the con-
rol group (n  12), 0.1 mL of 0.4% dimethyl sulfoxide in 0.1 M
hosphate-buffered saline was injected into the left femoral vein
0 minutes before spinal cord I/R injury. In the U0126-treated
roup (U0126 group, n  12), U0126 (100 g/kg in 0.1 mL of
.4% dimethyl sulfoxide, Promega Corporation, Madison, Wis), a
pecific inhibitor of MEK1/2, was injected intravenously instead.
n the sham-operated rats (n  3), exsanguination was induced in
he same way. The Fogarty catheter was inserted into the thoracic
orta and left there for 5 minutes without inflation of the balloon,
ollowed by restoration of blood volume. Rats were sacrificed
nder deep anesthesia at designated time points after injury. The
egment of lumbar enlargement was cut transversely into 2 pieces.
ne was put into liquid nitrogen and stored at 80°C, and the
ther was fixed with formalin and embedded in paraffin. Only the
umbar segment was used for evaluation because of its vulnera-
ility to ischemic injury.26
ssessment of Neurologic Dysfunction
ind limb motor function was evaluated 3 hours after I/R injury
nd then daily until 7 days, based on a modified grading scale.24
he grades were as follows: 0, no neurologic deficit (normal); 1,
ild weakness and/or gait disturbance, walking with toes flat
nder body; 2, knuckle-walking; 3, observable movements in the
ind limbs, but unable to knuckle-walk; and 4, complete paralysis
ith or without spasticity. Rats not showing grade 3 or grade 4
ysfunction of at least 1 hind limb 3 hours after I/R injury were
xcluded. In rats with apparent asymmetry of motor function
etween the 2 hind limbs, the worse score was recorded.
mmunohistochemistry
ix-micrometer sections were deparaffinized and rehydrated. An-
igen retrieval was done in boiled citrate buffer. A biotinylated sec-
ndary antibody (Immunotech, Marseille, France) was used. The
ntigen-antibody complexes were visualized using a streptavidin-
and Cardiovascular Surgery ● Volume 133, Number 4 935
h
c
t
e
n
N
C
s
t
i
i
b
a
m
m
a
c
i
D
S
T

t
j
P
K
s
M
p
m
t
e
S
D
h
I
p
W
S
I
R
I
0
o
m
w
(
w
m
m
t
i
E
L
s
c
E
i
p
e
p
d
s
c
s
e
m
N
S
A
s
U
r
m
t
o
3
U
g
v
a
.
N
N
g
I
s
o
l
a
i
l
a
o
b
2
4
g
(
o
h
Cardiopulmonary Support and Physiology Lu et al
9
CSPorseradish peroxidase reagent (Immunotech) with amino-ethyl
arbazol chromogen substrate (Immunotech). Sections were coun-
erstained with hematoxylin.
The expression of phosphorylated ERK1/2 (p-ERK1/2) was
xamined with a p-ERK1/2 antibody (1:100, Cell Signaling Tech-
ology, Beverly, Mass). Neuronal survival was evaluated using a
euN antibody (1:400, Chemicon International Inc, Temecula,
alif). The total number of neurons showing cytoplasmic NeuN
taining in the gray matter on a section was counted. To investigate
he nature of the cells infiltrating into the infarct area after I/R
njury, sections were incubated with either 1 of 4 antibodies,
ncluding myeloperoxidase (MPO) antibody (1:100, Abcam, Cam-
ridge, UK), a marker for polymorphonuclear neutrophils;27 CD14
ntibody (1:100, Santa Cruz Biotechnology, Santa Cruz, Calif), a
arker for macrophages;28 OX42 (1:50, Serotec, Oxford, UK), a
arker for microglia;29 and glial fibrillary acidic protein (GFAP)
ntibody (1:100, NeoMarkers, Fremont, Calif). The incubation
ondition was 4°C overnight for MPO, CD14, and OX42 antibod-
es, and room temperature for 1 hour for GFAP antibody.
etermination of Interleukin-1 Content in
pinal Cords
he lumbar segment of spinal cord was homogenized on ice in 300
L of phosphate-buffered saline (pH 7.4) with a mixture of pro-
ease inhibitors (Pierce, Rockford, Ill). Homogenates were sub-
ected to centrifugation at 13,000 rpm at 4°C for 20 minutes.
rotein concentration was determined with the BCA Protein Assay
it (Pierce, Rockford, Ill). The IL-1 content in spinal cord
amples was quantified with a human IL-1 ELISA kit (Bender
edSystems, Vienna, Austria) according to the manufacturer’s
rotocol. The change in absorbance on each well at 450 nm was
easured by a spectrophotometer (TEAN DU-800 UV/Vis Spec-
rophotometer, Mannedorf, Switzerland). The IL-1 level was
xpressed as nanograms per microgram of total protein.
tatistical Analysis
ata are presented as mean  standard deviation. Comparisons of
ind limb motor function, numbers of NeuN-positive cells, and
L-1 levels between the control and the U0126 groups were
erformed using a nonparametric method followed by the Mann-
hitney U test. Statistical analyses were conducted with the
tatistical Package for the Social Sciences 10.0 software (SPSS
nc, Chicago, Ill).
esults
n all rats, the rectal temperature was maintained at 37°C 
.5°C during surgery. The mean body weight of sham-
perated rats was 371.8  9.7 g (362-385 g, n  3). The
ean body weights of the control group and U0126 group
ere 375.9 7.1 g (367-388 g, n 12) and 369.0 11.3 g
354-389 g, n 12), respectively. The mean volume of blood
ithdrawn to reduce the CBP to 50 mm Hg was 5.8  1.1
L (4.8-7.2 mL) in the sham group, 6.0  0.8 mL (4.3-7.1
L) in the control group, and 5.7  0.5 mL (4.8-6.8 mL) in
he U0126 group. No significant differences in these phys-
ologic parameters existed between the groups. d
36 The Journal of Thoracic and Cardiovascular Surgery ● ApriRK1/2 Phosphorylation
ow-level constitutive expression of p-ERK1/2 was ob-
erved in the sham-operated spinal cord samples. In the
ontrol group, I/R injury resulted in a strong induction of
RK1/2 phosphorylation in the spinal cord at 3 hours after
njury. U0126 pretreatment completely abolished ERK1/2
hosphorylation, as reflected by the absence of p-ERK1/2
xpression. No significant difference of total ERK1/2 ex-
ression, used as an internal control, was observed between
ifferent samples (Figure 1, A ). Immunohistochemistry
howed faint p-ERK1/2 expression on sham-operated spinal
ord sections. Strong p-ERK1/2 immunostaining was ob-
erved in neurons and glial cells on control sections. How-
ver, on U0126 sections, p-ERK1/2 immunoreactivity was
arkedly suppressed (Figure 1, B).
eurologic Performance
ham-operated rats were neurologically intact after surgery.
ll rats of the control and U0126 groups demonstrated
evere motor weakness of hind limbs at 3 hours after injury.
0126-treated rats tended to show more obvious functional
ecovery thereafter. Although improvement of hind limb
otor function was also observed in the control group, the
rend was less apparent. On the contrary, functional deteri-
ration was not uncommon in the control group. Except for
hours (P  .752) and 1 day (P  .265) after injury, the
0126 group showed a significantly favorable functional
rading than the control group at all time points of obser-
ation (P  .032 at 2 days, P  .032 at 3 days, P  .025
t 4 days, P  .027 at 5 days, P  .037 at 6 days, and P 
019 at 7 days) (Figure 2).
euronal Survival
euN immunohistochemistry of spinal cord sections showed
reat distinction between the control and the U0126 groups.
n the control group, exuberant infiltration of hematoxylin-
tained cells associated with dramatic loss of neurons was
bserved 3 days after injury (Figure 3, A). This was fol-
owed by extensive tissue destruction and cavity formation
t 7 days (Figure 3, B). In contrast, the intensity of cellular
nfiltration and the severity of tissue damage and neuronal
oss were all much milder in the U0126 group (Figure 3, C
nd D), giving rise to the histopathologic feature observed
n a sham-operated section (Figure 3, E). The mean num-
ers of Neu-N-positive neurons per section were 367.8 
6.9 (n  3) in the sham-operated rats; 139.6  20.6 (n 
) at 3 days and 126.5 33.0 (n 4) at 7 days in the control
roup; and 293.3 42.4 (n 4) at 3 days and 284.0 39.9
n  4) at 7 days in the U0126 group. The mean numbers
f surviving neurons in the U0126 group were significantly
igher than in the control group at 3 days (P  .021) and 7
ays (P  .021) (Figure 3, F).
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Picroglial and Astroglial Reactions
n the basis of the distinction of cellular infiltration be-
ween the control and the U0126 groups, we further inves-
igated the nature of the infiltrating cells. Immunohisto-
hemistry using different antibodies showed that these
nfiltrating cells were not immunostained by the MPO or
Figure 1. Effects of I/R injury and U0126 on ERK1/2 ph
p-ERK1/2 in spinal cord samples obtained at 3 hours a
constitutive expression of p-ERK1/2 was observed in t
increase of p-ERK1/2 expression (C). Pretreatment wi
B, Immunohistochemistry of p-ERK1/2 on spinal cord
operated sections. Strong neuronal p-ERK1/2 expressio
treatment. Scale bar: 50 m. ERK, Extracellular signal
igure 2. All rats showed severe hind limb motor dysfunction 3
ours after injury. U0126 group showed functional recovery sig-
ificantly better than the control group (*P < .05, n  4 per timeUoint in both groups).
The Journal of ThoracicD14 antibodies, but only by the OX42 antibody. The
nfarct area was surrounded by cells demonstrating dense
FAP immunostaining and morphologic features of reac-
ive astrocytes (Figure 4).
pinal Cord Interleukin-1 Content
he calculated mean IL-1 amount (nanograms/microgram
f total protein) in the sham-operated cord samples was
.02  1.50 (n  4). The mean spinal cord IL-1 amounts
n the control group were 20.38 2.49 (n 4) at 1 day and
9.69 3.21 (n 4) at 3 days. The mean spinal cord IL-1
mounts in the U0126 group were 9.73  2.49 (n  4) at 1
ay and 8.67  2.27 (n  4) at 3 days. The IL-1 levels in
he control group were significantly higher than the sham
alue (P  .021 for both time points). The IL-1 levels in
he U0126 group were significantly lower than those in the
ontrol group (P  .021 for both time points). No signifi-
ant difference existed between the U0126 and the sham-
perated samples (P  .149 for 1 day, and P  .564 for 3
ays) (Figure 5).
iscussion
he major findings in this study regarding the effect of the
pecific MEK1/2 inhibitor U0126 on spinal cord I/R injury
re as follows. U0126 showed a potent inhibitory effect on
RK1/2 phosphorylation in spinal cords after I/R injury.
revious studies demonstrated that this inhibitory effect of
orylation. A, Western blot showing the expression of
injury, ERK1/2 being used as an internal control. Low
am-operated sample (S). I/R injury induced an abrupt
126 completely blocked ERK1/2 phosphorylation (U).
ions. Faint immunostaining was observed on sham-
s induced by I/R injury, which was abolished by U0126
lated kinase.osph
fter
he sh
th U0
sect
n wa
-regu0126 on ERK1/2 phosphorylation is dose dependent.9,13,23
and Cardiovascular Surgery ● Volume 133, Number 4 937
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CSPlthough Namura and colleagues13 showed maximal reduc-
ion of infarction volume after cerebral ischemia in mice
ith a U0126 dose of 200 g/kg, it was clear from their
eport that half-dose (100 g/kg) pretreatment achieved
lmost the same protective effect. On the basis of these
ndings, in the present study, we chose to use the minimally
equired 100 g/kg dose as our treatment regimen. Our data
ave proved this dose regimen effective both in inhibiting
RK1/2 phosphorylation and in reducing ischemic damage
f the spinal cord in rats. Another interesting issue regarding
Figure 3. Neu-N immunohistochemistry of spinal cord
groups at 3 days (A, C) and 7 days (B, D) after injury. Ex
in A), tissue destruction, and cavitation (arrows in B
treatment dramatically alleviated the injury severity, r
nostaining (C, D), a histopathologic feature on the sh
numbers of NeuN-positive cells per section were signi
(*P  .021). Compared with the sham, the mean numbe
for 3 days and 7 days), whereas those in the U0126 grou
.564 for 7 days).0126 administration is the timing. Wang and colleagues23 T
38 The Journal of Thoracic and Cardiovascular Surgery ● Apriemonstrated that U0126 injected 20 minutes after middle
erebral artery occlusion had no effect in reducing ERK1/2
hosphorylation. Namura and colleagues13 also showed that
he efficacy of U0126 in reducing brain infarct volume after
erebral ischemia declined with time in posttreatment com-
ared with pretreatment. In a preliminary experiment, we
ound that U0126 given intravenously 1 hour after spinal
ord I/R injury (100 g/kg) failed to inhibit ERK1/2 phos-
horylation. These findings suggest that ERK1/2 phosphor-
lation is an early event triggered by the ischemic insult.
ons obtained from the control (A, B) and U0126 (C, D)
ant cellular infiltration in the infarct area (arrowheads
to severe neuronal loss in the control group. U0126
ing in more surviving neurons showing NeuN immu-
perated section (E). Scale bar, 200 m. F, The mean
tly higher in the U0126 group than in the control group
the control group were significantly lower (P  .021
re not significantly different (P  .149 for 3 days, P secti
uber
) led
esult
am-o
fican
rs in
p weherefore, pretreatment before ischemia is a rational ap-
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Proach when pharmacologic abolishment of the MEK/ERK
athway is desired.
Despite the accumulating data showing beneficial effects
f U0126, the mechanisms underlying its neuroprotection
till remain elusive. In the present study, we observed
evere cellular infiltration into the infarct area associated
ith markedly elevated IL-1 production after I/R injury.
mmunohistochemical studies showed that the infiltrating
ells were not immunostained by the MPO, CD14, or GFAP
ntibodies, but reactive to the OX42 antibody. Because the
X42 antibody used in our study was directed against
igure 5. IL-1 content measured by enzyme-linked immunosor-
ent assay. I/R injury significantly increased IL-1 levels in the
ontrols (black bars). U0126 (gray bars) reduced IL-1 to values
omparable to that in the sham group (white bar) (*P  .021).(L, Interleukin.
The Journal of ThoracicD11b, an important surface marker of microglia,29 the
X42 immunoreactivity indicates that the infiltrating cells
ere neither neutrophils nor macrophages, but microglia in
ature. Microglia are considered the principal immune ef-
ector cells of the CNS responding to a variety of pathologic
vent.30 It is believed that neurotoxic molecules and surface
arkers expressed by activated microglia are detrimen-
al.31-35 Previous evidence has also shown that IL-1 is a
ritical cytokine released by activated microglia in an early
eriod after cerebral ischemia.33 These data, together with
ur findings, strongly support the importance of inflamma-
ory processes in the pathogenesis of CNS I/R injury.
The link between the MEK/ERK pathway and inflam-
atory cascades is unclear. In different types of cells,
lockade of the MEK/ERK pathway with a selective in-
ibitor PD98059 was shown to inhibit arachidonic acid
elease.36-38 Similarly, U0126 inhibited IL-1– dependent
rachidonic acid release in cells.39 More recently, it was
emonstrated that inhibiting the ERK1/2 pathway with
0126 significantly reduced proinflammatory cytokine IL-1
xpression in focal cerebral ischemia.23 In the present study,
EK/ERK inhibition with U0126 dramatically reduced mi-
roglial accumulation and IL-1 expression, resulting in
mproved neuronal survival. Taken together, these data sug-
est a role of the MEK/ERK pathway in the inflammatory
esponses after CNS ischemia, and that neuroprotection
rovided by U0126 is at least in part mediated by its inhibitory
ffects on microglial activation and IL-1 production.
The GFAP-stained cells adjacent to the infarct area
emonstrated features of reactive astrocytes, including hy-
ertrophy and process extension, as described previously
Figure 4. Immunohistochemistry of
spinal cord sections from the control
group at 3 days using MPO, CD14,
OX42, and GFAP antibodies, respec-
tively. The OX42-stained infiltrating
cells in the infarct area and the GFAP-
stained cells in the surrounding areas
indicate that microglial and astroglial
activation was a major pathologic fea-
ture after injury. Scale bar, 50 m.
MPO, myeloperoxidase; GFAP, glial
fibrillary acidic protein.Figure 4).40 Reactive astrocytes are a prominent feature of
and Cardiovascular Surgery ● Volume 133, Number 4 939
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CSPellular response to various forms of CNS injury. Although
eactive astrocytes were found to provide activities that
rotect tissue and preserve function after mild or moderate
pinal cord injury,41 reactive astrogliosis has been generally
egarded as a major impediment to axonal regeneration and
etrimental to functional outcome.42-44 Further studies are
arranted to elucidate the roles of reactive astrocytes in
pinal cord I/R injury.
onclusions
/R injury of the spinal cord induced ERK1/2 phosphoryla-
ion followed by pronounced microglial infiltration and
L-1 production. By inhibiting the MEK/ERK pathway,
0126 significantly attenuated cellular infiltration and cy-
okine production, resulting in neuronal and functional sal-
age. The MEK/ERK pathway appears to be an important
ediator of inflammatory reactions after I/R injury of the
pinal cord and may serve as a potential therapeutic target of
harmacologic interventions.35
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